» Articles » PMID: 30709391

Activation Therapy for the Treatment of Inpatients with Depression - Protocol for a Randomised Control Trial Compared to Treatment As Usual

Overview
Journal BMC Psychiatry
Publisher Biomed Central
Specialty Psychiatry
Date 2019 Feb 3
PMID 30709391
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Inpatients with depression have a poor long term outcome with high rates of suicide, high levels of morbidity and frequent re-admission. Current treatment often relies on pharmacological intervention and focuses on observation to maintain safety. There is significant neurocognitive deficit which is linked to poor functional outcomes. As a consequence, there is a need for novel psychotherapeutic interventions that seek to address these concerns.

Methods: We combined cognitive activation and behavioural activation to create activation therapy (AT) for the treatment of inpatient depression and conducted a small open label study which demonstrated acceptability and feasibility. We propose a randomised controlled trial which will compare treatment as usual (TAU) with TAU plus activation therapy for adult inpatients with a major depressive episode. The behavioural activation component involves therapist guided re-engagement with previously or potentially rewarding activities. The cognitive activation aspect utilises computer based exercises which have been shown to improve cognitive function.

Discussion: The proposed randomised controlled trial will examine whether or not the addition of this therapy to TAU will result in a reduced re-hospitalisation rate at 12 weeks post discharge. Subjective change in activation and objectively measured change in activity levels will be rated, and the extent of change to neurocognition will be assessed.

Trial Registration: Unique trial number: U1111-1190-9517. Australian New Zealand Clinical Trials Registry (ANZCTR) number: ACTRN12617000024347p .

Citing Articles

Can circadian rhythm predict changes in neurocognitive functioning in bipolar disorder: protocol of a 12-month longitudinal cohort study based on research domain criteria.

Luo H, Wang X, Zhang Y, Li J, Hu R, Zhang Z Ann Med. 2023; 55(2):2240422.

PMID: 37506182 PMC: 10392262. DOI: 10.1080/07853890.2023.2240422.


The Relationship between Depressive Symptoms, Rumination, and Suicide Ideation in Patients with Depression.

Chiang Y, Ma Y, Lin Y, Jiang J, Wu M, Chiang K Int J Environ Res Public Health. 2022; 19(21).

PMID: 36361367 PMC: 9658339. DOI: 10.3390/ijerph192114492.


Frequency of suicide ideation and attempts and its correlates among inpatients with depressive disorders at a tertiary care center in North India.

Belsiyal C, Rentala S, Das A J Family Med Prim Care. 2022; 11(6):2537-2544.

PMID: 36119260 PMC: 9480815. DOI: 10.4103/jfmpc.jfmpc_2013_21.


MicroRNA-139-5p acts as a suppressor gene for depression by targeting nuclear receptor subfamily 3, group C, member 1.

Su B, Cheng S, Wang L, Wang B Bioengineered. 2022; 13(5):11856-11866.

PMID: 35543383 PMC: 9276025. DOI: 10.1080/21655979.2022.2059937.


Can Cognitive Control and Attentional Biases Explain More of the Variance in Depressive Symptoms Than Behavioral Processes? A Path Analysis Approach.

Krings A, Simon J, Carre A, Blairy S Front Psychol. 2022; 13:809387.

PMID: 35401370 PMC: 8985875. DOI: 10.3389/fpsyg.2022.809387.


References
1.
Conradi H, Ormel J, de Jonge P . Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2010; 41(6):1165-74. DOI: 10.1017/S0033291710001911. View

2.
Folke F, Hursti T, Tungstrom S, Soderberg P, Kanter J, Kuutmann K . Behavioral activation in acute inpatient psychiatry: a multiple baseline evaluation. J Behav Ther Exp Psychiatry. 2014; 46:170-81. DOI: 10.1016/j.jbtep.2014.10.006. View

3.
Reppermund S, Zihl J, Lucae S, Horstmann S, Kloiber S, Holsboer F . Persistent cognitive impairment in depression: the role of psychopathology and altered hypothalamic-pituitary-adrenocortical (HPA) system regulation. Biol Psychiatry. 2006; 62(5):400-6. DOI: 10.1016/j.biopsych.2006.09.027. View

4.
Montgomery S, Asberg M . A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134:382-9. DOI: 10.1192/bjp.134.4.382. View

5.
Walsh B, Seidman S, Sysko R, Gould M . Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002; 287(14):1840-7. DOI: 10.1001/jama.287.14.1840. View